MLTX
Moonlake Immunotherapeutics
NASDAQ · Biotechnology
$15.51
+0.74 (+5.01%)
Open$14.90
Previous Close$14.77
Day High$15.62
Day Low$14.83
52W High$62.75
52W Low$5.95
Volume—
Avg Volume1.19M
Market Cap1.11B
P/E Ratio—
EPS$-3.33
SectorBiotechnology
Analyst Ratings
Strong Buy
24 analysts
Price Target
-32.0% upside
Current
$15.51
$15.51
Target
$10.54
$10.54
$8.06
$10.54 avg
$16.98
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 207.37M | 195.61M | 178.47M |
| Net Income | -41,056,867 | -38,376,149 | -44,335,912 |
| Profit Margin | -19.8% | -19.6% | -24.8% |
| EBITDA | -81,449,014 | -69,654,675 | -60,804,840 |
| Free Cash Flow | -45,845,658 | -33,391,408 | -32,934,200 |
| Rev Growth | +19.2% | +9.7% | +1.7% |
| Debt/Equity | 0.11 | 0.10 | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |